Johnson & Johnson Stock - weekly review and sector check

Edited by ad hoc news Sector & Peer-Group Desk. Verified prior to publication on 06/19/2026, 13:00 UTC. Details in the imprint.

Johnson & Johnson (US4781601046) is ending the week with a modest pullback after a strong prior run. The move comes as large US healthcare names show a softer tone alongside a recent downtick in the broader market, according to sector data.

How the week shaped up

Johnson & Johnson shares recently closed around $228 on the New York Stock Exchange, down roughly 2.5% from the prior session’s close, based on delayed quote data as of 06/18/2026.

That leaves the stock still comfortably above the $200 level seen earlier this year, highlighting a solid year-to-date performance despite the latest step back.

Peer comparison in healthcare

On a weekly view, the decline in Johnson & Johnson mirrors a softer patch for large US healthcare and pharmaceutical names, with several blue chips also edging lower in recent sessions according to sector screens.

Overall, the stock’s market capitalization remains around $550 billion, keeping Johnson & Johnson among the largest constituents of the Standard & Poor's 500 index and a heavyweight in global healthcare benchmarks.

How the company makes money

Johnson & Johnson generates revenue across three main segments: innovative medicines, medtech devices and consumer health products, including well-known brands such as Tylenol and Band-Aid, according to the company’s latest corporate overview.

Where the stock trades today

The shares of Johnson & Johnson (US4781601046) trade on the New York Stock Exchange at $228.38 as of 06/18/2026, 16:00 ET.

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.